Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics is a promising clinical-stage biotechnology company that is focused on developing therapies for heart diseases through three interrelated platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. The recent FDA clearance for the clinical hold on TN-201, and the encouraging clinical results for TN-401, demonstrate the company's strong scientific capabilities and potential for success. The company has a diverse pipeline and a strong team of experienced scientists and medical professionals, which positions it well for future growth and success.

Bears say

Tenaya Therapeutics is a clinical-stage company focused on gene therapy and precision medicine for heart disease, but their early-stage programs and lack of human proof-of-concept data present significant risks and potential delays to bringing their products to market. Additionally, there is competition in the rare genetic disorders space and an uncertain market potential for their potential one-time gene therapy treatments. With a need for continued fundraising and a lack of a clear pathway to profitability, there are significant financial risks associated with investing in Tenaya Therapeutics.

Tenaya Therapeutic (TNYA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.